01:08

Advances in managing ARIA in patients with Alzheimer’s disease treated with donanemab

01:30

Recommendations for the appropriate use of donanemab in Alzheimer’s disease

01:07

Swedish BioFINDER-2: investigating the diagnostic accuracy of p-tau217 for Alzheimer’s disease

01:54

Challenges in developing anti-Aβ monoclonal antibodies for Alzheimer’s disease

05:37

The development of lecanemab for the treatment of early Alzheimer’s disease

01:20

Measuring clinically relevant change in apathy symptoms in AD using data from the ADMET trials

04:35

A study investigating nabilone for the treatment of agitation in AD

01:08

The value and limitations of p-tau217 in AD clinical trials

04:48

Advances in fluid biomarker research for the treatment of neurodegenerative diseases

01:31

Comparing different assays for detecting AD plasma biomarkers

03:13

CS6253: a novel peptide with the potential to lower the risk of Alzheimer’s disease

04:42

PreventE4: evaluating the role of omega-3 in cognitive health and Alzheimer’s disease

04:42

The great debate: defining AD beyond amyloid-β

01:55

Novel therapeutics being explored in AD and moving towards combination approaches

03:09

Tyrosine kinase inhibitors in neurodegenerative diseases and lessons learned from cancer treatment

03:31

Understanding agitation in Alzheimer’s disease and current approaches to management

03:26

Lecanemab: slowing the progression of AD and the potential for subcutaneous administration

02:13

Using a p-tau217 assay to screen participants for the ALTITUDE-AD trial

01:43

The ALTITUDE-AD trial: targeting soluble amyloid-β oligomers with sabirnetug in AD

02:47

The potential of targeting omega-3 metabolism in the brain to prevent AD

06:25

The International Working Group’s new recommendations for diagnosing AD

09:37

A Phase II trial of nilotinib in patients with dementia with Lewy bodies

05:00

An automated speech tool to screen for cognitive impairment: a study in four European cohorts

02:09

The need for digital tools to assess cognition in Alzheimer's disease

03:32

Using blood testing to improve the accuracy of AD diagnosis in primary and secondary care settings

01:02

Comparing plasma ptau217 with CSF biomarkers for predicting tau PET status

02:27

The accuracy of plasma tau217 biomarkers in detecting AD pathology

04:34

Using plasma ptau217 to select cognitively unimpaired participants for AD prevention trials

06:13

The association between infectious diseases and dementia

02:09

Highlights from AAIC 2024: tau-PET harmonization and the DIAN-TU trial

01:50

The clinical use of tau-PET: its value and limitations

05:57

Improving tau-PET harmonization: the HEAD study

04:19

Looking back over the first year of lecanemab use in AD: benefits and challenges

05:12

The minimum acceptable performance of blood biomarker tests for diagnosing AD

07:08

A head-to-head comparison of AD blood tests reveals the value of ptau217

05:25

The evolution of biomarker testing in AD: CSF, blood, and PET

03:39

Fueling dementia policy change on an international level

08:11

The spread of oligomeric tau through synapses in Alzheimer's disease

01:27

Harnessing resilience mechanisms to prevent neuronal loss in Alzheimer's disease

01:37

The impact of meditation on mental health and well-being in aging

01:33

Introducing novel AD biomarkers into clinical practice: how close are we?

02:20

How society needs to be made ready to treat Alzheimer’s disease

01:25

Inspiring advances in research through scientific meetings

02:18

The potential of brain-derived tau as a neurodegeneration biomarker

01:47

Metabolome-wide association studies in Alzheimer's disease

01:00

Interactions between Aβ and tau proteins in Alzheimer’s disease

03:05

Sex differences in Alzheimer's disease plasma biomarkers

02:27

Polygenic risk scores for Alzheimer's disease in relation to cognitive change

01:47

Tau-targeted therapy landscape in Alzheimer’s disease

01:46

Next steps in anti-amyloid immunotherapy

01:24

Markers of of tau pathology in Alzheimer’s disease

02:42

Updates on tau topography and propagation

06:52

Metabolomics analysis of the FINGER trial

01:46

The direction of disease-modifying therapeutic development in Alzheimer’s disease

04:48

Subtyping mixed primary progressive aphasia

02:24

Shaping future care: biomarker advances in Alzheimer’s Disease

01:44

Challenges in fluid biomarker development in Alzheimer's disease research

01:13

Neuroprotective effects of transcription factor NRF2 in Alzheimer’s disease mice models

03:09

How are blood-based biomarkers currently used in Alzheimer’s disease?

01:12

ALZ-801 in combination with anti-amyloid antibodies for the treatment of Alzheimer’s disease